S Gastrointestinal And Liver Disease 12th Edition [work] «720p»
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
With a new senior editorial team leading the way, this edition ensures that practitioners have access to the latest, most evidence-based information in the rapidly evolving field of gastroenterology. What’s New in the 12th Edition?
Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease . 12th ed. Elsevier; 2020. s gastrointestinal and liver disease 12th edition
The textbook is organized logically across 11 primary sections comprising 132 chapters:
The 12th edition proudly welcomes a new senior editorial team, representing a new generation of leaders in the field: This is for informational purposes only
The 12th Edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease is not just a textbook; it is an investment in clinical excellence. By successfully marrying the intricate science of pathophysiology with the practical demands of modern management, it remains the undisputed authority in the field. For any medical professional serious about mastering gastroenterology, this text remains an essential addition to their library.
The is available in multiple formats:
: A new chapter on Enterocolitis and Hepatitis induced by cancer immunotherapy, reflecting the rise of biological treatments in oncology. Microbiota and Probiotics
The 12th edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease is not simply an updated textbook; it is a comprehensive, modern, and practical guide that arrives at a pivotal time. With a new editorial team at the helm, it brilliantly balances the wisdom of its storied past with the urgent needs of contemporary clinical practice. The addition of new chapters on COVID-19 manifestations, cancer immunotherapy side effects, and AI in endoscopy demonstrates a profound commitment to staying ahead of the curve. Learn more With a new senior editorial team
: Extensive new data on biologics and novel small molecules for treating and preventing IBD recurrences. Obesity Management
